Index -
P/E -
EPS (ttm) -3.97
Insider Own 1.35%
Shs Outstand 55.27M
Perf Week 5.92%
Market Cap 1.47B
Forward P/E -
EPS next Y -5.50
Insider Trans -15.67%
Shs Float 54.23M
Perf Month 5.01%
Income -218.00M
PEG -
EPS next Q -1.56
Inst Own 109.02%
Short Float / Ratio 10.68% / 12.01
Perf Quarter 13.84%
Sales 19.00M
P/S 77.44
EPS this Y 28.30%
Inst Trans -3.05%
Short Interest 5.79M
Perf Half Y -14.91%
Book/sh 18.76
P/B 1.43
EPS next Y 11.30%
ROA -18.10%
Target Price 37.40
Perf Year 36.28%
Cash/sh 13.47
P/C 1.99
EPS next 5Y 39.00%
ROE -20.20%
52W Range 16.75 - 34.76
Perf YTD -4.49%
Dividend -
P/FCF -
EPS past 5Y 8.90%
ROI -22.80%
52W High -22.84%
Beta 0.94
Dividend % -
Quick Ratio 17.30
Sales past 5Y -19.80%
Gross Margin 89.90%
52W Low 60.12%
ATR 1.00
Employees 389
Current Ratio 17.50
Sales Q/Q 600.00%
Oper. Margin -
RSI (14) 63.41
Volatility 3.98% 3.56%
Optionable Yes
Debt/Eq 0.00
EPS Q/Q 15.60%
Profit Margin -
Rel Volume 0.78
Prev Close 26.06
Shortable Yes
LT Debt/Eq 0.00
Earnings May 04 BMO
Payout -
Avg Volume 482.26K
Price 26.82
Recom 2.20
SMA20 3.67%
SMA50 12.31%
SMA200 -0.61%
Volume 376,827
Change 2.92%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-03-23 Initiated
Piper Sandler
Overweight
$41
Nov-17-22 Upgrade
Goldman
Sell → Neutral
$17 → $32
Jul-27-22 Upgrade
SVB Leerink
Mkt Perform → Outperform
$33
Dec-03-21 Initiated
BofA Securities
Buy
$54
Jul-30-21 Downgrade
Goldman
Neutral → Sell
$58 → $39
Jul-01-21 Initiated
Raymond James
Mkt Perform
Jun-10-21 Initiated
H.C. Wainwright
Buy
$88
Mar-01-21 Upgrade
SVB Leerink
Mkt Perform → Outperform
$50
Mar-01-21 Downgrade
JP Morgan
Overweight → Neutral
$64 → $54
Feb-26-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
Oct-22-20 Upgrade
Barclays
Equal Weight → Overweight
$46
Mar-04-20 Initiated
Barclays
Equal Weight
$50
Nov-26-19 Initiated
Cantor Fitzgerald
Overweight
$64
Sep-23-19 Upgrade
Guggenheim
Neutral → Buy
$55
May-23-19 Resumed
Goldman
Neutral
$55
Feb-15-19 Upgrade
SVB Leerink
Mkt Perform → Outperform
$80
Sep-25-18 Initiated
Leerink Partners
Mkt Perform
May-23-18 Initiated
Citigroup
Buy
$117
Apr-11-18 Reiterated
Credit Suisse
Outperform
$80 → $95
Feb-15-18 Reiterated
SunTrust
Buy
$80 → $101
Show Previous Ratings
Jun-05-23 07:00AM
May-30-23 09:45AM
May-25-23 09:55AM
07:00AM
May-11-23 10:00AM
09:55AM
Loading…
May-09-23 09:55AM
May-08-23 07:55AM
May-05-23 10:50AM
May-04-23 11:23PM (Thomson Reuters StreetEvents) +7.65%
08:25AM
07:00AM
Apr-25-23 07:00AM
Apr-19-23 07:00AM
Apr-13-23 07:00AM
Apr-12-23 08:00AM
01:19PM
Loading…
Apr-09-23 01:19PM
Apr-03-23 07:00AM
Mar-15-23 11:44AM
Mar-11-23 09:10AM
Mar-05-23 05:20AM
Mar-02-23 08:26AM
Feb-28-23 07:00AM
Feb-24-23 12:00PM
11:49AM
Feb-23-23 08:45AM
08:38AM
07:00AM
Feb-09-23 09:40AM
Feb-02-23 07:00AM
Jan-15-23 08:56AM
08:00PM
Loading…
Jan-08-23 08:00PM
Jan-03-23 05:57PM
Dec-24-22 10:07AM
Dec-21-22 08:00AM
Dec-11-22 07:00PM
Dec-10-22 06:30PM
Dec-06-22 07:00AM
Nov-30-22 08:00AM
Nov-17-22 05:52AM (American City Business Journals) +5.38%
Nov-11-22 11:03AM
Nov-10-22 04:01PM
Nov-09-22 05:36AM
Nov-04-22 12:20PM
Nov-03-22 09:00AM
08:25AM
08:00AM (Thomson Reuters StreetEvents)
07:00AM
Oct-27-22 04:01PM
Oct-20-22 07:00AM
Oct-02-22 09:44AM
Sep-26-22 07:13PM
Sep-19-22 07:00AM
Sep-16-22 06:41AM
Sep-06-22 08:05AM
Sep-02-22 04:02PM (Investor's Business Daily)
Aug-24-22 07:00AM
Aug-18-22 06:35PM
Aug-15-22 08:00AM
Aug-11-22 06:35PM
10:01AM
Aug-08-22 06:36PM
08:41AM
Aug-05-22 12:20PM
Aug-04-22 08:45AM
07:00AM
Jul-14-22 07:00AM
Jul-12-22 04:01PM (American City Business Journals)
04:01PM
Jun-13-22 06:30AM
Jun-10-22 10:30AM
Jun-02-22 05:39PM
May-17-22 12:13PM
May-16-22 04:15PM (American City Business Journals)
04:15PM
May-12-22 10:00AM
May-10-22 07:00AM
May-07-22 09:02AM
May-05-22 08:15AM
07:00AM
Apr-21-22 07:00AM
Apr-14-22 08:34AM
Mar-01-22 08:35AM
Feb-28-22 07:00AM
Feb-24-22 05:49PM
12:03PM
08:55AM
07:00AM
Feb-23-22 12:57PM
Feb-18-22 10:29AM
05:41AM
Feb-17-22 03:41PM
03:03PM
Feb-10-22 07:00AM
Feb-08-22 01:38PM
Jan-18-22 02:57PM
Jan-10-22 01:38PM
07:00AM
Dec-22-21 07:00AM
Dec-21-21 04:27AM
Dec-17-21 11:38PM
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
FOUSE JACQUALYN A Director Apr 08 Option Exercise 0.00 15,933 0 98,515 Apr 12 04:17 PM Schenkein David P Director Apr 03 Option Exercise 9.05 16,363 148,085 134,242 Apr 05 04:03 PM Schenkein David P Director Apr 03 Sale 22.85 16,363 373,895 117,879 Apr 05 04:03 PM Schenkein David P Director Mar 27 Option Exercise 9.05 20,000 181,000 137,879 Mar 29 09:30 PM Schenkein David P Director Mar 27 Sale 22.15 20,000 443,000 117,879 Mar 29 09:30 PM Schenkein David P Director Mar 13 Option Exercise 9.05 20,000 181,000 137,879 Mar 15 05:11 PM Schenkein David P Director Mar 13 Sale 22.49 20,000 449,817 117,879 Mar 15 05:11 PM Washburn Theodore James Jr. Principal Accounting Officer Mar 03 Sale 24.29 504 12,242 2,741 Mar 07 04:02 PM Washburn Theodore James Jr. Principal Accounting Officer Mar 01 Option Exercise 0.00 777 0 3,518 Mar 03 04:08 PM Gheuens Sarah Chief Medical Officer Mar 01 Option Exercise 0.00 3,833 0 21,250 Mar 03 04:05 PM Schenkein David P Director Feb 27 Option Exercise 9.05 20,000 181,000 137,879 Mar 01 04:06 PM Schenkein David P Director Feb 27 Sale 25.37 20,000 507,400 117,879 Mar 01 04:06 PM Washburn Theodore James Jr. Principal Accounting Officer Feb 16 Sale 27.21 233 6,340 2,668 Feb 21 04:05 PM Washburn Theodore James Jr. Principal Accounting Officer Feb 14 Option Exercise 0.00 360 0 3,532 Feb 16 04:04 PM FOUSE JACQUALYN A Director Feb 14 Option Exercise 0.00 11,333 0 86,230 Feb 16 04:03 PM Burns James William Chief Legal Officer Feb 14 Option Exercise 0.00 1,738 0 24,147 Feb 16 04:04 PM Washburn Theodore James Jr. Principal Accounting Officer Feb 14 Sale 28.59 504 14,409 2,901 Feb 16 04:04 PM Schenkein David P Director Feb 13 Option Exercise 9.05 20,000 181,000 137,879 Feb 15 04:03 PM Schenkein David P Director Feb 13 Sale 28.62 20,000 572,400 117,879 Feb 15 04:03 PM Burns James William Chief Legal Officer Feb 10 Option Exercise 0.00 1,834 0 23,052 Feb 14 04:07 PM Washburn Theodore James Jr. Principal Accounting Officer Feb 10 Option Exercise 0.00 777 0 3,445 Feb 14 04:06 PM Schenkein David P Director Jan 30 Option Exercise 9.05 20,000 181,000 137,879 Feb 01 04:04 PM Schenkein David P Director Jan 30 Sale 29.33 20,000 586,578 117,879 Feb 01 04:04 PM Schenkein David P Director Jan 17 Option Exercise 9.05 20,000 181,000 137,879 Jan 19 04:03 PM Schenkein David P Director Jan 17 Sale 28.85 20,000 577,093 117,879 Jan 19 04:03 PM Burns James William Chief Legal Officer Dec 23 Option Exercise 0.00 8,750 0 23,815 Dec 28 04:05 PM Gheuens Sarah Chief Medical Officer Dec 23 Option Exercise 0.00 9,375 0 18,388 Dec 28 04:05 PM Gheuens Sarah Chief Medical Officer Dec 02 Option Exercise 0.00 833 0 9,261 Dec 06 04:14 PM Poddar Richa Chief Commercial Officer Oct 15 Option Exercise 0.00 5,000 0 9,993 Oct 18 04:17 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite